Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up